NEUMORA THERAPEUTICS, INC. Operating Income
NEUMORA THERAPEUTICS, INC. (NMRA) reported Operating Income of -$42.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$42.19M.
- NEUMORA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$52.86M.
- NEUMORA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$58.48M.
- NEUMORA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$57.70M.
- NEUMORA THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$241.16M.
- NEUMORA THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$263.46M.
- NEUMORA THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$252.10M.
- NEUMORA THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$135.87M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$42.19M 10-Q · filed 2026-08-14 | -$95.05M 10-Q · filed 2026-08-14 | -$153.53M derived: sum of 3 quarters · filed 2026-08-14 | -$211.23M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$52.86M 10-Q · filed 2026-05-07 | -$111.34M derived: sum of 2 quarters · filed 2026-05-07 | -$169.04M derived: sum of 3 quarters · filed 2026-05-07 | -$223.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$58.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$116.18M derived: sum of 2 quarters · filed 2026-03-30 | -$170.22M derived: sum of 3 quarters · filed 2026-08-14 | -$241.16M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$57.70M 10-Q · filed 2025-11-06 | -$111.74M derived: sum of 2 quarters · filed 2026-08-14 | -$182.68M 10-Q · filed 2025-11-06 | -$245.60M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$54.04M 10-Q · filed 2026-08-14 | -$124.98M 10-Q · filed 2026-08-14 | -$187.90M derived: sum of 3 quarters · filed 2026-08-14 | -$264.54M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$70.94M 10-Q · filed 2026-05-07 | -$133.86M derived: sum of 2 quarters · filed 2026-05-07 | -$210.50M derived: sum of 3 quarters · filed 2026-05-07 | -$274.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$62.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$139.57M derived: sum of 2 quarters · filed 2026-03-30 | -$203.39M derived: sum of 3 quarters · filed 2026-03-30 | -$263.46M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$76.65M 10-Q · filed 2025-11-06 | -$140.47M derived: sum of 2 quarters · filed 2025-11-06 | -$200.54M 10-Q · filed 2025-11-06 | -$314.55M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$63.82M 10-Q · filed 2025-08-06 | -$123.90M 10-Q · filed 2025-08-06 | -$237.90M derived: sum of 3 quarters · filed 2025-08-06 | -$294.76M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$60.07M 10-Q · filed 2025-05-12 | -$174.08M derived: sum of 2 quarters · filed 2025-05-12 | -$230.94M derived: sum of 3 quarters · filed 2025-05-12 | -$273.00M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$114.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$170.87M derived: sum of 2 quarters · filed 2025-03-03 | -$212.93M derived: sum of 3 quarters · filed 2025-03-03 | -$252.10M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$56.86M 10-Q · filed 2024-11-12 | -$98.93M derived: sum of 2 quarters · filed 2024-11-12 | -$138.09M 10-Q · filed 2024-11-12 | -$168.81M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$42.06M 10-Q · filed 2024-08-06 | -$81.23M 10-Q · filed 2024-08-06 | -$111.95M derived: sum of 3 quarters · filed 2025-03-03 | -$142.55M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$39.17M 10-Q · filed 2024-05-07 | -$69.89M derived: sum of 2 quarters · filed 2025-03-03 | -$100.49M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2022-12-31 | -$30.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$61.32M derived: sum of 2 quarters · filed 2025-03-03 | -$135.87M 10-K · filed 2025-03-03 | |
| 2022-09-30 | -$30.60M 10-Q · filed 2023-11-01 | -$105.15M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |